PRESS: BusinessCann “Celadon Pharma Says It Wants To Deliver Its ‘Trial and Product As A Holistic Package’ Overseas Amid First Update Since AIM Listing”

Celadon Pharmaceuticals, the first British cannabis company to list on the Alternative Investments Market (AIM) since GW Pharmaceuticals, recently released an update on its business.
CEO James Short is focused on the company’s long-term goals, such as expanding the Canpain trial overseas and securing a contract with the National Health Service (NHS).
Read more: https://businesscann.com/celadon-pharma-says-it-wants-to-deliver-its-trial-and-product-as-a-holistic-package-overseas-amid-first-update-since-aim-listing/
OTHER POSTS
-
PRESS: British Pain Society features Celadon Pharmaceuticals Plc
-
BUSINESS UPDATE: Celadon Pharmaceuticals Plc (CEL) Announces Interim Results
-
PRESS: Inside huge top-secret legal cannabis facility hidden away in Birmingham that is the size of three football pitches
-
PRESS: Celadon Pharmaceutical’s CEO Jim Short featured discussing new MHRA framework